Please wait
 
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

Date of Report: August 18, 2026

 

Commission File Number: 001-39307

 

 

Legend Biotech Corporation

(Exact Name of Registrant as Specified in its Charter)

 

 

 

77 Corporate Drive

Bridgewater, New Jersey 08807

(Address of principal executive office)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F  ☒            Form 40-F  ☐

 

 

 

 

 

 

 

 

 

 

Legend Biotech Corporation (the “Company”) will hold its Annual General Meeting of Shareholders (the “Meeting”) on September 24, 2026 beginning at 9:00 a.m. (local time) at the Company’s offices at 77 Corporate Drive, Bridgewater, New Jersey 08807, USA.

 

Materials made available in connection with the Meeting are available on the Company's website at www.legendbiotech.com. The information contained in, or that can be accessed through, the Company’s website is not a part of this filing.

 

The following documents regarding the Meeting, each of which are attached as an exhibit hereto, are incorporated by reference herein. This report on Form 6-K, including the exhibits attached hereto, shall be deemed to be incorporated by reference in the registration statements of the Company on Form F-3 (Nos. 333-278050 and 333-257625) and Form S-8 (Nos. 333-239478 and 333-283217), to the extent not superseded by documents or reports subsequently filed.

 

EXHIBIT INDEX

     
Exhibit   Title
   
99.1   Proxy Statement
99.2   Notice of Annual General Meeting
99.3   Form of Proxy
99.4   Voting Card and Instructions for ADS Holders

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

       
 

LEGEND BIOTECH CORPORATION

(Registrant)

     
August 18, 2026 By:  

/s/ Alan Bash

      Alan Bash
      Interim Chief Executive Officer